S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
NASDAQ:ILMN

Illumina - ILMN Stock Forecast, Price & News

$214.26
-10.68 (-4.75%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$213.18
$221.24
50-Day Range
$188.77
$224.94
52-Week Range
$173.45
$371.16
Volume
1.14 million shs
Average Volume
1.30 million shs
Market Capitalization
$33.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$252.32

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
17.8% Upside
$252.32 Price Target
Short Interest
Healthy
2.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.07mentions of Illumina in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$499,481 Sold Last Quarter
Proj. Earnings Growth
-37.05%
From $2.24 to $1.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

354th out of 1,028 stocks

Analytical Instruments Industry

10th out of 27 stocks

ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Piper Sandler Trims Illumina (NASDAQ:ILMN) Target Price to $290.00
Has Illumina taken the wrong path in its Grail quest?
Analysts Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $253.00
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
What's in the Cards for Illumina (ILMN) in Q4 Earnings?
Illumina (NASDAQ:ILMN) Downgraded by Argus to Hold
Sequencing the Sustainable Secrets of Seaweed
Illumina PT Lowered to $300 at Canaccord Genuity
Should You Hold Illumina (ILMN)?
What’s Happening With Illumina Stock?
Illumina Remains A Sell After 2023 Guidance
Illumina Selected as One of America's Most JUST Companies
5 big earnings reports: Bed Bath & Beyond, Illumina
Illumina (ILMN), Nashville Biosciences Partner With Amgen
Illumina challenges EU order to keep Grail separate
Illumina Slumps as 2023 Profit Outlook Disappoints Street
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
11/04/2021
Today
2/05/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,150
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$252.32
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$175.00
Forecasted Upside/Downside
+17.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
15 Analysts

Profitability

Net Income
$762 million
Pretax Margin
-86.87%

Debt

Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.16 per share
Book Value
$68.71 per share

Miscellaneous

Free Float
157,096,000
Market Cap
$33.70 billion
Optionable
Optionable
Beta
1.13

Social Links


Key Executives

  • Francis A. deSouzaFrancis A. deSouza
    President, Chief Executive Officer & Director
  • Kevin Pegels
    Chief-Global Operations
  • Joydeep Goswami
    Chief Financial & Strategy Officer
  • Phillip G. FebboPhillip G. Febbo
    Chief Medical Officer
  • Alex Aravanis
    CTO, Head-Research & Product Development













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2023?

15 Wall Street research analysts have issued 12-month price objectives for Illumina's shares. Their ILMN share price forecasts range from $175.00 to $350.00. On average, they anticipate the company's stock price to reach $252.32 in the next year. This suggests a possible upside of 17.8% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2023?

Illumina's stock was trading at $202.20 at the beginning of 2023. Since then, ILMN shares have increased by 6.0% and is now trading at $214.26.
View the best growth stocks for 2023 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our ILMN earnings forecast
.

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Tuesday, February 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings results on Thursday, November, 4th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.21. The life sciences company earned $1.11 billion during the quarter, compared to analyst estimates of $1.04 billion. Illumina had a positive trailing twelve-month return on equity of 4.36% and a negative net margin of 88.40%. The firm's quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.02 earnings per share.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY23 earnings guidance on Tuesday, January, 10th. The company provided earnings per share (EPS) guidance of $1.25-1.50 for the period, compared to the consensus earnings per share estimate of $3.03. The company issued revenue guidance of $4.90-5.03 billion, compared to the consensus revenue estimate of $5.04 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.64%), Sarasin & Partners LLP (0.35%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Douglas Lane & Associates LLC (0.19%), Natixis Advisors L.P. (0.18%) and CCLA Investment Management (0.13%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $214.26.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $33.70 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or ($26.40) on an earnings per share basis.

How many employees does Illumina have?

The company employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 2/5/2023 by MarketBeat.com Staff